Concord Pharma introduced new anti-diabetic Dapazin (Dapagliflozin)

dapazin-launchingA new Horizon has been opened for Diabetes treatment.  Concord Pharmaceuticals Ltd. proudly introduced the new oral antidiabetic drug Dapazin (Dapagliflozin), for the first time in Bangladesh which may reduce insulin dependency in millions of diabetic patients in the future.

Concord Pharmaceuticals has launched US FDA Approved latest anti-diabetic drug Dapagliflozin as brand name Dapazin (5 mg Tablet).

The Legend Diabetes Specialist & The President of the Bangladesh Diabetic Association Prof. Dr. A K Azad Khan inaugurated the launching of Dapazin on 28 Aug ’15 in Dhaka Regency Hotel & Resort. Major General Md. Mustafizur  Rahman, Directorate General of Drug Administration (DGDA) was present as a special guest.

The Keynote speaker Prof. Dr.  M A Hasanat, Chairman, Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU) & Assistant Prof. Dr. Shahjada Selim delivered the clinical presentation. Prof. Dr. Hajera Mahtab, Prof. Dr. M. A. Mannan, Prof. Dr. Laique Ahamed Khan, Prof. Dr. Abdul Mannan Sarker, and  Prof. Dr. Md. Nazrul Islam Siddiqui were present as Expert Panel.

The Specialist Doctors Informed that Dapazin may help to control Blood glucose with an additional reduction of hypertension and body weight. They also added that in the near future, Dapazin may reduce the insulin dose and dependency of diabetic patients.  There are more than 200 Diabetic specialists and other doctors from different corners of the country were present in the program. Chairman, Md. Faizur Rahman and Managing Director, Md. Saidur Rahman of Concord Pharmaceuticals Ltd. welcomed the entire invited guest to the program.

Check Also

Novo Nordisk raises awareness about diabetes

(Saykot Murtaza): Novo Nordisk, a Danish multinational pharmaceutical company, will observe World Health Day on …

Leave a Reply

Your email address will not be published. Required fields are marked *